Wasawas, Nilda T.
HRN: 13-38-22 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/15/2023
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
04/15/2023
04/22/2023
IV
2.25g
Q6
Dm Foot
Waiting Final Action
Indication: Empiric Type of Infection: Bone & Joint Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes